KidneyCAN is dedicated to accelerating kidney cancer research

Our advocacy for the DOD Kidney Cancer Research Program resulted in appropriations of  $40 million in fiscal year 2020  for kidney cancer research. In 2016, this number was $0.

Our Kidney Cancer Research Summit brings translational researchers in kidney cancer together in an annual collaborative meeting.  Additionally, KidneyCAN’s  “Rock the Cure” events have raised over $1,000,000 toward private research support.


KidneyCAN is proud to have hosted the second annual Kidney Cancer Research Summit, a meeting focused on basic and translational science, as well as cutting edge translational research. This work is fueled by the funding from the Department of Defense CDMRP – KCRP.

The Kidney Cancer Research Summit (#KCRS20) was scheduled for October 22nd-23rd in Philadelphia, Pennsylvania. Given the complications of COVID-19, we held a virtual conference instead. Despite the challenges, #KCRS20 was an incredible meeting of scientists and clinicians, attended by hundreds of people from 41 countries across the globe!

You can see all #KCRS20 presentations and videos at our event site, linked below. Questions? Contact us at [email protected].



The Kidney Cancer Research Summit (#KCRS19) took place on September 12-13, 2019. Led by Dr. Toni Choueiri (Dana Farber Cancer Institute) and Dr. Hans Hammers (University of Texas Southwest Medical Center), this event brought together some of the most promising ideas for treatment.

KidneyCAN gathered 150 of the key thought leaders in the kidney cancer field. Researchers, scientists, and clinicians, along with government and industry partners, had an opportunity to gather in one location and share their latest findings in a collaborative and discussion-centric environment.

#KCRS19 Presentations

If you missed #KCRS19, you can review the presentation content here.

“This is what started as a grassroots meeting for the entire RCC community, focusing on science, ultimate collaboration, and inclusiveness. All in the hope of helping our patients live better,  live longer, and dream of the cure. Why not? Isn’t that what we all want if we get this disease?

I feel this is the beginning of something very, very special.”

Toni Choueiri, MD, Dana-Farber Cancer Institute

“It’s one of the most exciting things I’ve ever participated in. We’re bringing together clinicians, physician scientists, and bench scientists to talk about kidney cancer research. The goal is to invigorate the science and spur breakthroughs.”

Hans Hammers, MD, PhD, UT Southwestern Medical Center

Thinking Outside the Tumor: Tumor Microenvironment and Epigenetics

Moderated by Eric Jonasch & Monty Pal

Modeling the Effects of Stroma on Clear Cell Renal Cell Carcinoma
(Leif Oxburgh)

Histone-Dependent PARP-1 Inhibitors: A Novel Therapeutic Modality for the Treatment of Renal Cell Carcinoma (Vladimir Kolenka)

Kinase Signaling and Extracellular Matrix Proteolysis in Kidney Cancer
(Dimitri Bourboulia)

Chromatin Dysregulation and Metabolism Disorder in Kidney Cancer
(Laura Banaszynski)

Novel Methods of Drug Delivery

Moderated by Robert Uzzo & Michael Mitchell

Overcoming Biological Barriers (Michael Mitchell)

Combining Immunotherapy with Nanoparticles for Improved Kidney Cancer Outcomes (Paula Bates)

Generating Systemic Antitumor Immunity in RCC by Intratumoral Injection of Multiplexed Anti-PD-1 Antibody and Adenosine Deaminase (Wilson Meng)

Reinvigorating Antitumor Immunity in Renal Cell Carcinoma with Nanoparticulate STING Agonists (John Wilson)

Single Cell Sequencing Strategies in Kidney Cancer

Moderated by Payal Kapur & Sabina Signoretti

Introduction to Single Cell Sequencing in Solid Cancers (Ari Hakimi)

Single Cell Architecture of Mitochondrial DNA Mutations in RCC (Eduard Reznik)

Using Single-Cell Transcriptomics to Understand Tumor and Immune Heterogeneity Driving Resistance (David Braun)

Scientific Mentoring Session Powered by the American Urological Association

Introduction to AUA (Carolyn Best)

Introduction to Scientific Mentoring Session (Brian Rini)

Poster Sessions from AUA by Ken Batai, Phillip Abbosh, Vivek Narayan, and Brandon Manley (R. Uzzo, B. Shuch, A. Kutikov, E. Singer, G. Bratslavsky)

Novel Checkpoint Inhibitors and Cellular Immunotherapy

Moderated by Hans Hammers & Charles Drake

Is VISTA:VSIG3 an Actionable Immune Checkpoint Target (Kathleen Mahoney)

Identification of a New Immune Checkpoint Pathway in RCC (Rupal Bhatt)

Development and Potentials for ImmunoPET Imaging (David Leung)

HERV-E TCR Transduced Autologous T Cells (Rosa Nadal)

Overview of Cellular Therapies: CAR-T (Regina Young, introduction by Naomi Haas)

Targeting B7-H3 in Renal Cell Carcinoma via CAR-T Cells (Hongwei Du)

Design of Dual Targeted CAR-T Cells to Improve RCC Treatment Safety (Wayne Marasco)

Predictive Biomarkers

Moderated by Michael Atkins & Marie Carlo

Predictive Biomarkers for Nivolumab Treatment in Metastatic Renal Cell Carcinoma from Checkmate-25 (Sabina Signoretti & Toni Choueiri)

Predictive Biomarkers for VEGF Inhibitors in RCC (Maxine Sun)

Biomarkers: Where Do We Go from Here? (Brian Rini)

Bridging Academia and Industry Through Biomarker Work in RCC (Paul Robbins)

Collaborations in Kidney Cancer Research

Moderated by Toni Choueri & Chris Wood

DOD Overview, CDMRP, KCRP (Theresa Miller, introduced by Bryan Lewis)

DOD Consortium Development Award (Eric Jonasch)

Renal Task Force: Trial: Focus on Small Renal Masses and Biomarkers (Michael Jewett)

SPORE Projects: UTSW (Jim Brugarolas)

SPORE Projects DF/HCC (Toni Choueiri)

KCA Research Initiatives (Chris Wood, Gretchen Vaughn)

Panel Discussion: Stakeholder Collaborations in the Kidney Cancer Community (Led by Bryan Lewis)

Translational Variants in Rare Kidney Cancers

Moderated by Marston Linehan & Kim Rathmell

Setting the Stage to Research and Collaborations in Rare Kidney Cancer Variants (James Hsieh)

Novel Function of the Tumor Suppressor FLCN in Rare Kidney Cancer (Mehdi Mollapour)

Chromophobe RCC: New Insights (Elizabeth Henske)

Novel Mechanism of Pathogenesis for Renal Medullary Carcinoma (Pavlos Msaouel)

Therapeutic Targeting TFE3 in Translocation Renal Cell Carcinoma (Roberto Pili & Nur Damayanti)

Papillary RCC (Brian Shuch, with Nizar Tannir)

“Kidney cancer is the ideal sandbox for these new approaches, and without a doubt the same approach can, should and will be suitable for other cancers.”

Dr. Hans Hammers